Clinical Trial

Safety, Tolerability and Pharmacokinetic Study of HRS-8829

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction（DDI）
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Status change: Not Yet Recruiting → Completed 2026-04-23
Trial Details
NCT Number NCT07083362
Lead Sponsor Beijing Suncadia Pharmaceuticals Co., Ltd
Conditions Acute Ischemia Stroke
Enrollment 83 participants
Start Date 2025-08-06
Primary Completion 2026-01-12 (estimated)
Study Completion 2026-01-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-28